NASDAQ:AKTX
Akari Therapeutics Plc Stock Company Profile
$1.18
+0.0138 (+1.18%)
At Close: Apr 22, 2024
Information
75/76 Wimpole Street
London NY W1G 9RT
44 20 8004 0270
www.akaritx.com
Industry: Biotechnology
Sector: Healthcare
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
